• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis - Product Image

Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis

  • Published: November 2012
  • 45 pages
  • GlobalData

Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’s SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

Eli Lilly and Company and Incyte Corporation are jointly developing baricitinib, an oral JAK1 and 2 inhibitor, under a worldwide license and collaboration agreement in which Lilly has the licensing rights. Baricitinib prevents intracellular signaling of IL-6 and IL-23, thereby reducing inflammation. Formerly known as LY3009104 to Lilly and as INCB28050 to Incyte, baricitinib is currently in Phase IIb clinical trials to study patients with active RA on background MTX. This trial is READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Overview
4.2 Diagnosis
4.3 Treatment
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 More rheumatologists in the field and physician knowledge of the disease
6.2.2 More cost-effective therapies through oral formulation and biosimilars
6.2.3 The development of predictive tests and discovery of biomarkers
6.2.4 The discovery of curative therapies
6.2.5 Improved drug safety and efficacy profiles
6.3 Gap Analysis
6.4 Opportunities
6.4.1 Predictive tools for diagnosis and treatment
6.4.2 Target specificity
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
8 Baricitinib (formerly LY3009104/INCB28050)
8.1 Overview
8.2 Efficacy
8.3 Safety
8.4 Dosing and Formulation
8.5 Potential Clinical Positioning
8.6 Potential Commercial Positioning
8.7 Pricing and Reimbursement
8.8 SWOT Analysis
8.9 Forecast
9 Appendix
9.1 Abbreviations
9.2 Bibliography
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed Rheumatoid Arthritis Patients
9.4.2 Percent Drug-treated Patients
9.4.3 General Pricing Assumptions
9.4.4 Pricing of Pipeline agents
9.5 Physicians and Specialists Included in this Study
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Analysts
9.7.2 Global Head of Healthcare
9.8 About Us
9.9 Contact Us
9.10 Disclaimer

1.1 List of Tables
Table 1: Symptoms of Rheumatoid Arthritis
Table 2: Treatment Guidelines for Rheumatoid Arthritis
Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market
Table 4: Treatment Guidelines for Rheumatoid Arthritis
Table 5: Overall Unmet Needs - Current Level of Attainment
Table 6: Clinical Unmet Needs - Gap Analysis, 2012
Table 7: Rheumatoid Arthritis - Phase Pipeline, 2012
Table 8: Comparison of Therapeutic Classes in Development for RA, 2012
Table 9: Product Profile - Baricitinib
Table 10: ACR Responses for Baricitinib + MTX vs. Placebo + MTX at Week 12
Table 11: Safety of 4 and 8mg Baricitinib at Week 12
Table 12: Laboratory Values of 4 and 8mg Baricitinib at Week 12
Table 13: Baricitinib SWOT Analysis, 2012
Table 14: Global Sales Forecasts ($m) for Baricitinib
Table 15: Physicians Surveyed, By Country

1.2 List of Figures
Figure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis
Figure 2: Rheumatoid Arthritis Biologic Drug Targets
Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria Point System
Figure 4: Severity of Rheumatoid Arthritis
Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations-
Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2012-2022

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos